Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China

AIM: To determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced ejection fraction in China and to provide evidence-based reference for clinical rational drug selection and medical decision-making. RESEARCH DESIGN AND METHODS: We used the Markov model to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Haiqiang, Wan, Yiming, Ma, Zhenzhou, Zhang, Shengye, Zhao, Qiuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708714/
https://www.ncbi.nlm.nih.gov/pubmed/36465457
http://dx.doi.org/10.3389/fcvm.2022.1022020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708714/
https://www.ncbi.nlm.nih.gov/pubmed/36465457
http://dx.doi.org/10.3389/fcvm.2022.1022020

Ejemplares similares